AI Science Tracker
EN

Novel artificial intelligence-enabled deep learning system to enhance adenoma detection: a prospective randomized controlled study

Affiliation not stated in the reviewed material · 28 Feb 2023 · medicine

Discovery

Novel artificial intelligence-enabled deep learning system to enhance adenoma detection: a prospective randomized controlled study

Source check: Source checked. Not independent scientific confirmation.

Finding: A prospective randomized study of 674 white-light colonoscopies found higher adenoma detection with the DEEP2 computer-aided detection system (37% vs 27%; 122/330 vs 93/344) and more adenomas per colonoscopy, with about four false alerts per AI exam. The result is a bounded single-center clinical detection outcome. PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.

Technology: PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

AI contribution
PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
Test and result
PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result.
Limitation / still unknown
PMC12850877 Methods/Results: randomized 1:1 comparison, 1,033 enrolled and 674 analyzed after protocol exclusions; pathology-confirmed lesions; ADR and APC; unblinded study, single center, false alerts recorded by endoscopists. Existing catalog 2020 CADe trial is a different paper/system and cohort; not same result. The source does not establish benefits beyond the reported evaluation.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12850877/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.